[Form 4] Dianthus Therapeutics, Inc. /DE/ Insider Trading Activity

Dianthus Therapeutics CEO and President Garcia Marino exercised stock options on March 16, 2026 to acquire a total of 65,292 shares of common stock.

Rhea-AI Filing Summary

Dianthus Therapeutics CEO and President Garcia Marino exercised stock options on March 16, 2026 to acquire a total of 65,292 shares of common stock. This came from options for 59,700 shares at $6.70 per share and 5,592 shares at $17.88 per share. Following these exercises, Marino holds 65,292 common shares directly, while some option awards continue to vest over time according to their original schedules.

Insider Trade Summary

65,292 shares exercised/converted

Exercise 4 txns

Insider Garcia Marino

Role CEO AND PRESIDENT

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	59,700	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	5,592	$0.00	$0.00
Exercise	Common Stock	59,700	$6.70	$400K
Exercise	Common Stock	5,592	$17.88	$100K

Holdings After Transaction: Stock Option (Right to Buy) — 269,449 contracts (Direct); Common Stock — 65,292 shares (Direct)

Footnotes (2)

1. F1. The shares of common stock underlying this stock option award vested as to 25% of the shares on November 1, 2022, with the remaining three quarters vested in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
2. F2. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 05:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Garcia Marino

(Last) (First) (Middle)

C/O DIANTHUS THERAPEUTICS, INC.

7 TIMES SQUARE, 43RD FLOOR

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dianthus Therapeutics, Inc. /DE/ [ DNTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO AND PRESIDENT

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		M		59,700	A	$6.7	59,700	D
Common Stock	03/16/2026		M		5,592	A	$17.88	65,292	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.7	03/16/2026		M			59,700	(1)	11/03/2031	Common Stock	59,700	$0	41	D
Stock Option (Right to Buy)	$17.88	03/16/2026		M			5,592	(2)	01/23/2034	Common Stock	5,592	$0	269,408	D

Explanation of Responses:

1. The shares of common stock underlying this stock option award vested as to 25% of the shares on November 1, 2022, with the remaining three quarters vested in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

2. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Adam Veness, as attorney-in-fact for Marino Garcia	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.